Desert King
  • Nosotros
  • Materias Primas
    • Administración de Materias Primas: Quillaja
    • Administración de Materias Primas: Yucca
    • Administración de Materias Primas: Jojoba
  • Líneas de Negocio
    • Farmacéutica
    • Nutrición y Salud Animal
    • Alimentación y Bebidas
    • Cuidado Personal y Cosmética
    • Agricultura
    • Medio ambiente y minería
  • Calidad
  • Noticias
  • Canal de Denuncias
  • Contacto
  • Inglés
  • Español
La Opción Natural La Opción Natural La Opción Natural La Opción Natural
  • Nosotros
  • Materias Primas
    • Administración de Materias Primas: Quillaja
    • Administración de Materias Primas: Yucca
    • Administración de Materias Primas: Jojoba
  • Líneas de Negocio
    • Farmacéutica
    • Nutrición y Salud Animal
    • Alimentación y Bebidas
    • Cuidado Personal y Cosmética
    • Agricultura
    • Medio ambiente y minería
  • Calidad
  • Noticias
  • Canal de Denuncias
  • Contacto
  • Inglés
  • Español

Texto Cientifico

Zabala, B.A., et al. Induction of Sustained Immunity Following Vaccination with Live Attenuated Trypanosoma cruzi Parasites Combined with Saponin-Based Adjuvants. Biology (Basel), 2025 Sep 20, 14(9):1298.
0
By Desert King
In Texto Cientifico
Posted 8 octubre, 2025

Zabala, B.A., et al. Induction of Sustained Immunity Following Vaccination with Live Attenuated Trypanosoma cruzi Parasites Combined with Saponin-Based Adjuvants. Biology (Basel), 2025 Sep 20, 14(9):1298.

Zabala, B.A., et al. Induction of Sustained Immunity Following Vaccination with Live Attenuated Trypanosoma cruzi Parasites Combined with Saponin-Based Adjuvants. Biology (Basel), 2025 Sep 20, [...]

READ MORE
Cao, H., et al. A Comparative Study on Immune Protection Efficacy: An HSV-1 Trivalent Antigen Subunit Vaccine Formulated with a Cellular Immunity-Inducing Adjuvant Versus an mRNA Vaccine. Vaccines (Basel), 2025 Sep 10, 13(9):958.
0
By Desert King
In Texto Cientifico
Posted 8 octubre, 2025

Cao, H., et al. A Comparative Study on Immune Protection Efficacy: An HSV-1 Trivalent Antigen Subunit Vaccine Formulated with a Cellular Immunity-Inducing Adjuvant Versus an mRNA Vaccine. Vaccines (Basel), 2025 Sep 10, 13(9):958.

Cao, H., et al. A Comparative Study on Immune Protection Efficacy: An HSV-1 Trivalent Antigen Subunit Vaccine Formulated with a Cellular Immunity-Inducing Adjuvant Versus an mRNA Vaccine. [...]

READ MORE
Bissa, M., et al. HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. Nat Commun, 2025 Sep 29, 16(1):8571.
0
By Desert King
In Texto Cientifico
Posted 8 octubre, 2025

Bissa, M., et al. HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. Nat Commun, 2025 Sep 29, 16(1):8571.

Bissa, M., et al. HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. Nat Commun, 2025 Sep 29, 16(1):8571. PMID: 41022728 This paper explores [...]

READ MORE
Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China. Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the [...]

READ MORE
Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192. PMID: 40804241 This study supports a [...]

READ MORE
Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30. PMID: 40737310 LeishTec is a recombinant vaccine adjuvanted [...]

READ MORE
Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396. PMID: 40592255 This study [...]

READ MORE
Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, [...]

READ MORE
Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, [...]

READ MORE
Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913.
0
By Desert King
In Texto Cientifico
Posted 8 agosto, 2025

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913.

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913. PMID: 40692104 This study [...]

READ MORE

DESERT KING INTERNATIONAL
745 Main Street-
Chula Vista, CA, USA, 91911
+1 619 429 5222
info@desertking.com

DESERT KING CHILE
Avenida Industrial 1970
Quilpué, Chile, 2420505
+56 32 292 5020
info@desertking.cl

DESERT KING MEXICO
Camino Vecinal 11500-A
Tijuana B.C., México, 22664
+52 664 636 11 24
info@desertkingmexico.com

Politica de Privacidad
© 2025 Desert King. All Right Reserved

Start typing and press Enter to search